A Phase I/II Study Evaluating the Feasibility and Safety of Neoadjuvant Gemcitabine/Nab-paclitaxel (GA) and Concurrent Gemcitabine and Radiation Therapy Followed By Pancreatic Resection and Major Arterial Resection for Adenocarcinoma of the Pancreas (ARCAP) in Patients With Advanced Disease
Phase of Trial: Phase I/II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 04 Jan 2017 Status changed from not yet recruiting to recruiting.
- 21 Jun 2016 Planned initiation date changed from 1 Jul 2015 to 1 Jul 2016.
- 06 Jul 2015 New trial record